|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MCM7 |
Gene summary for MCM7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MCM7 | Gene ID | 4176 |
| Gene name | minichromosome maintenance complex component 7 | |
| Gene Alias | CDC47 | |
| Cytomap | 7q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000724 | UniProtAcc | C6EMX8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4176 | MCM7 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.18e-05 | 3.84e-01 | -0.0811 |
| 4176 | MCM7 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.12e-05 | 2.92e-01 | -0.1954 |
| 4176 | MCM7 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.39e-09 | 6.20e-01 | -0.1464 |
| 4176 | MCM7 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.68e-14 | 7.04e-01 | -0.059 |
| 4176 | MCM7 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.24e-06 | 5.64e-01 | -0.0842 |
| 4176 | MCM7 | HTA11_866_3004761011 | Human | Colorectum | AD | 6.60e-11 | 5.40e-01 | 0.096 |
| 4176 | MCM7 | HTA11_6801_2000001011 | Human | Colorectum | SER | 7.03e-07 | 9.59e-01 | 0.0171 |
| 4176 | MCM7 | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.57e-04 | 4.11e-01 | 0.0338 |
| 4176 | MCM7 | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.81e-14 | 5.87e-01 | 0.0674 |
| 4176 | MCM7 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.01e-22 | 7.35e-01 | 0.294 |
| 4176 | MCM7 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.04e-17 | 7.02e-01 | 0.3859 |
| 4176 | MCM7 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.08e-08 | 7.67e-01 | 0.2585 |
| 4176 | MCM7 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 9.52e-07 | 4.15e-01 | 0.3005 |
| 4176 | MCM7 | LZE7T | Human | Esophagus | ESCC | 3.34e-13 | 9.43e-01 | 0.0667 |
| 4176 | MCM7 | LZE20T | Human | Esophagus | ESCC | 1.77e-04 | 2.43e-01 | 0.0662 |
| 4176 | MCM7 | LZE21D1 | Human | Esophagus | HGIN | 7.61e-04 | 5.40e-01 | 0.0632 |
| 4176 | MCM7 | LZE22D1 | Human | Esophagus | HGIN | 4.04e-04 | 2.22e-01 | 0.0595 |
| 4176 | MCM7 | LZE22T | Human | Esophagus | ESCC | 3.08e-06 | 9.46e-01 | 0.068 |
| 4176 | MCM7 | LZE24T | Human | Esophagus | ESCC | 1.89e-13 | 3.29e-01 | 0.0596 |
| 4176 | MCM7 | LZE21T | Human | Esophagus | ESCC | 1.18e-09 | 6.21e-01 | 0.0655 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006261 | Liver | HCC | DNA-dependent DNA replication | 80/7958 | 151/18723 | 5.91e-03 | 2.44e-02 | 80 |
| GO:00062603 | Oral cavity | OSCC | DNA replication | 159/7305 | 260/18723 | 3.25e-13 | 1.59e-11 | 159 |
| GO:007084916 | Oral cavity | OSCC | response to epidermal growth factor | 37/7305 | 49/18723 | 2.21e-07 | 3.51e-06 | 37 |
| GO:00323925 | Oral cavity | OSCC | DNA geometric change | 59/7305 | 90/18723 | 3.03e-07 | 4.63e-06 | 59 |
| GO:007136416 | Oral cavity | OSCC | cellular response to epidermal growth factor stimulus | 34/7305 | 45/18723 | 6.73e-07 | 9.53e-06 | 34 |
| GO:00325083 | Oral cavity | OSCC | DNA duplex unwinding | 55/7305 | 84/18723 | 8.05e-07 | 1.12e-05 | 55 |
| GO:00063023 | Oral cavity | OSCC | double-strand break repair | 132/7305 | 251/18723 | 7.93e-06 | 8.52e-05 | 132 |
| GO:00062611 | Oral cavity | OSCC | DNA-dependent DNA replication | 84/7305 | 151/18723 | 2.46e-05 | 2.30e-04 | 84 |
| GO:000941018 | Oral cavity | OSCC | response to xenobiotic stimulus | 222/7305 | 462/18723 | 4.00e-05 | 3.48e-04 | 222 |
| GO:0006270 | Oral cavity | OSCC | DNA replication initiation | 25/7305 | 34/18723 | 4.63e-05 | 3.90e-04 | 25 |
| GO:0006310 | Oral cavity | OSCC | DNA recombination | 147/7305 | 305/18723 | 6.33e-04 | 3.56e-03 | 147 |
| GO:0000725 | Oral cavity | OSCC | recombinational repair | 70/7305 | 140/18723 | 5.22e-03 | 2.03e-02 | 70 |
| GO:0000724 | Oral cavity | OSCC | double-strand break repair via homologous recombination | 69/7305 | 138/18723 | 5.52e-03 | 2.14e-02 | 69 |
| GO:0006268 | Oral cavity | OSCC | DNA unwinding involved in DNA replication | 11/7305 | 15/18723 | 7.49e-03 | 2.75e-02 | 11 |
| GO:0000727 | Oral cavity | OSCC | double-strand break repair via break-induced replication | 9/7305 | 12/18723 | 1.27e-02 | 4.24e-02 | 9 |
| GO:000626011 | Oral cavity | LP | DNA replication | 97/4623 | 260/18723 | 3.67e-06 | 7.75e-05 | 97 |
| GO:007084917 | Oral cavity | LP | response to epidermal growth factor | 26/4623 | 49/18723 | 1.84e-05 | 3.14e-04 | 26 |
| GO:007136417 | Oral cavity | LP | cellular response to epidermal growth factor stimulus | 24/4623 | 45/18723 | 3.44e-05 | 5.18e-04 | 24 |
| GO:000941019 | Oral cavity | LP | response to xenobiotic stimulus | 141/4623 | 462/18723 | 2.33e-03 | 1.68e-02 | 141 |
| GO:000630211 | Oral cavity | LP | double-strand break repair | 80/4623 | 251/18723 | 5.81e-03 | 3.46e-02 | 80 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041109 | Esophagus | HGIN | Cell cycle | 38/1383 | 157/8465 | 6.70e-03 | 4.37e-02 | 3.47e-02 | 38 |
| hsa0411016 | Esophagus | HGIN | Cell cycle | 38/1383 | 157/8465 | 6.70e-03 | 4.37e-02 | 3.47e-02 | 38 |
| hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa030304 | Esophagus | ESCC | DNA replication | 32/4205 | 36/8465 | 7.71e-07 | 5.06e-06 | 2.59e-06 | 32 |
| hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0303011 | Esophagus | ESCC | DNA replication | 32/4205 | 36/8465 | 7.71e-07 | 5.06e-06 | 2.59e-06 | 32 |
| hsa041104 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
| hsa0411011 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
| hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa03030 | Oral cavity | OSCC | DNA replication | 31/3704 | 36/8465 | 1.70e-07 | 1.19e-06 | 6.03e-07 | 31 |
| hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa030301 | Oral cavity | OSCC | DNA replication | 31/3704 | 36/8465 | 1.70e-07 | 1.19e-06 | 6.03e-07 | 31 |
| hsa030302 | Oral cavity | LP | DNA replication | 23/2418 | 36/8465 | 1.08e-05 | 7.79e-05 | 5.02e-05 | 23 |
| hsa0411022 | Oral cavity | LP | Cell cycle | 70/2418 | 157/8465 | 1.17e-05 | 8.27e-05 | 5.33e-05 | 70 |
| hsa030303 | Oral cavity | LP | DNA replication | 23/2418 | 36/8465 | 1.08e-05 | 7.79e-05 | 5.02e-05 | 23 |
| hsa0411032 | Oral cavity | LP | Cell cycle | 70/2418 | 157/8465 | 1.17e-05 | 8.27e-05 | 5.33e-05 | 70 |
| hsa0411021 | Prostate | Tumor | Cell cycle | 51/1791 | 157/8465 | 5.67e-04 | 2.89e-03 | 1.79e-03 | 51 |
| hsa0411031 | Prostate | Tumor | Cell cycle | 51/1791 | 157/8465 | 5.67e-04 | 2.89e-03 | 1.79e-03 | 51 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MCM7 | SNV | Missense_Mutation | c.1175N>T | p.Ser392Leu | p.S392L | P33993 | protein_coding | deleterious(0) | possibly_damaging(0.732) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MCM7 | SNV | Missense_Mutation | novel | c.365C>G | p.Pro122Arg | p.P122R | P33993 | protein_coding | tolerated(0.06) | benign(0.015) | TCGA-AC-A5XU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
| MCM7 | SNV | Missense_Mutation | c.1869N>A | p.Asp623Glu | p.D623E | P33993 | protein_coding | tolerated(0.36) | benign(0.052) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MCM7 | SNV | Missense_Mutation | c.382N>A | p.Ala128Thr | p.A128T | P33993 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-C8-A1HL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MCM7 | SNV | Missense_Mutation | rs775586840 | c.1594N>T | p.Arg532Trp | p.R532W | P33993 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-D8-A1X9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
| MCM7 | SNV | Missense_Mutation | rs374121810 | c.214N>T | p.Arg72Cys | p.R72C | P33993 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
| MCM7 | SNV | Missense_Mutation | rs755514827 | c.491N>A | p.Arg164His | p.R164H | P33993 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-E9-A1N3-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| MCM7 | SNV | Missense_Mutation | novel | c.418N>C | p.Gly140Arg | p.G140R | P33993 | protein_coding | deleterious(0.04) | benign(0.027) | TCGA-OL-A66I-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| MCM7 | insertion | Frame_Shift_Ins | novel | c.970_971insCTGGAGGAGC | p.Leu324ProfsTer28 | p.L324Pfs*28 | P33993 | protein_coding | TCGA-A7-A4SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| MCM7 | insertion | Frame_Shift_Ins | novel | c.1055_1056insTCCTGGCTCAG | p.Lys352AsnfsTer11 | p.K352Nfs*11 | P33993 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |